Uppsala, March 20, 2079. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Chinese Patent Office (CHN) for the patent application no. 201480038696, “New Use of a Fluidic Device”.
Uppsala, Sweden, March 18, 2019. Speaking at the Novel Antimicrobials and AMR Diagnostics Conference in Berlin, Gradientech, developer of the QuickMIC™ rapid IVD system for antibiotic susceptibility testing (AST), stressed the importance of adopting new diagnostic approaches in the fight against antimicrobial resistance.
Uppsala, February 15, 2019. Gradientech AB has successfully transitioned to the latest revision of ISO13485:2016,an important regulatory requirement forCE-marking of our in vitrodiagnostic system QuickMIC™for ultra-rapid antibiotic susceptibility testing (AST). “We are very pleased to have obtained this certification, since it accredits that our company has the ability to provide medical devices that meet customer and internationalregulatoryrequirements”, said Sara Thorslund, co-founder and CEO of Gradientech.
Uppsala Sweden, August 30, 2018. The Swedish biotech and diagnostics firm Gradientech has successfully raised 20 MSEK ($2.2M) in equity funding among its existing investors.